Figure 9.

PRP6-HO7 modulates intrinsically activated surface markers in differentiating Mo-DCs and Mo-macrophages from active autoimmune SLE patients. Human Mo-DCs and Mo-macrophages from active SLE patients (cohort 2) were either left untreated or incubated with PRP6-HO7 at 32 nM throughout their differentiation process. Cells were then collected, washed, and analyzed by flow cytometry for cell surface expression of the activation markers CD64 (M0), or CD83, the co-stimulatory molecules CD86, CD80 and CD40, and HLA-DR (iDC). MFI, Both the median fluorescence intensity (MFI) and the percentage of positive cells for the different surface markers are indicated. The arrows indicate the MFI threshold of activity considered for each of the surface markers (CD64: 10000, CD83: 2500, CD86: 1000, CD80: 1500, CD40: 10000, HLA-DR: 2000). The results shown are the mean ± SD from 6-9 independent donors (*p < 0.05; **p < 0.01; ***p < 0.001 compared with M0 or iDC).